Oportuzumab monatox
As of the edition of 20 October 2026, Oportuzumab monatox is an antibody drug conjugate: of no established status; acts on EEF2 and EPCAM.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Antibody drug conjugate
- Registered trials
- 3, 0 stopped early
- Disease areas
- Cancer; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 3 | 2 | 1 | 0 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sesen Bio | Lead sponsor of trials | 2015 to now |
| Qilu Pharmaceutical | Lead sponsor of trials | 2021 to now |